Related Experiment Video
Updated: Jun 12, 2026
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
Descriptive Analysis of Retrospective Observational Real-World Evidence of a Monoclonal Anti-Amyloid Therapy Program
Tara C Carlisle1,2,3, Samantha K Holden4,5,6,7, Stefan Sillau4
1Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA. Tara.Carlisle@cuanschutz.edu.
Introduction:
Anti-amyloid therapy (AAT) protocol complexity may widen specialty dementia care access gaps. The University of Colorado (CU) Advanced Therapy in Neurodegenerative Disorders (ATND) Clinic is within the CU-Memory Disorders Clinic (CU-MDC). The aim of this study is to report initial CU-ATND real-world evidence (RWE).
Methods:
Patients who completed CU-ATND Clinic intake paperwork were included (n = 123) and compared to CU-MDC (n = 1100) seen between April 2024 to June 2025. Demographic information was included for both clinics. Retrospective observational data on CU-ATND Clinic patients including work-up, decisions about pursing AAT, and adverse events at the time of data extraction was described.
Results:
AAT status included patient declined (37.4%) or deferred (8.1%), clinically excluded (14.6%), undergoing work-up (8.1%), consented for infusions (26.0%), completed infusions (0.8%), and stopped infusions (4.1%). CU-ATND Clinic patients had a median age of 73 years and were 50.4% women with the majority white and urban-dwelling similar to the CU-MDC. AAT candidacy steps and decision duration varied. AAT-related adverse events were managed without extended inpatient admission or persistent effects.
Conclusion:
Many care disparities were present prior to CU-ATND referral. The CU-ATND RWE highlights successes and provides insight into barriers impacting access.